BioNexus Gene Lab(BGLC)

Focus: BioNexus Gene Lab is a public biotechnology company specializing in blood-based genomic screening, headquartered in Kuala Lumpur, Malaysia. The company operates at a modest revenue scale of approximately $10M annually with minimal R&D investment.

Profile data last refreshed 6h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About BioNexus Gene Lab

AI assessmentNot Hiring

No open roles listed right now. Follow BioNexus Gene Lab to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$10M

FY2025

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

SEC Filings: 2 available

Financials (FY2025)

Help build intelligence for BioNexus Gene Lab

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides liquidity and potential equity upside in an emerging genomics screening market
Specialization in blood-based diagnostics positions the company in a high-growth segment with significant clinical utility potential
Early-stage company offers opportunity to shape organizational culture and scientific direction from ground level

Watch Out For

Critically low R&D spending ($55K in FY2024) suggests minimal investment in product development and scientific innovation
Negative net income ($2.6M loss in FY2024) and declining revenue ($10M vs $11M YoY) indicate financial distress and sustainability concerns
Zero active job openings and no disclosed headcount data suggests minimal hiring activity and organizational contraction

Generated by Claude from BioNexus Gene Lab's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Revenue

$10M3%

R&D Spend

$48K(0%)14%

Net Income

-$2M

Cash

$3M

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo